Bonraybio Co., Ltd. (TPE:6955)
Taiwan · Delayed Price · Currency is TWD 162.00
+2.50 (1.57%)
At close: Jan 21, 2026
Bonraybio Revenue
Bonraybio had revenue of 73.26M TWD in the quarter ending September 30, 2025, with 28.41% growth. This brings the company's revenue in the last twelve months to 287.10M, up 36.00% year-over-year. In the year 2024, Bonraybio had annual revenue of 222.88M with 39.61% growth.
Revenue (ttm)
287.10M
Revenue Growth
+36.00%
P/S Ratio
13.99
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 222.88M | 63.24M | 39.61% |
| Dec 31, 2023 | 159.64M | 53.37M | 50.22% |
| Dec 31, 2022 | 106.27M | 49.98M | 88.78% |
| Dec 31, 2021 | 56.30M | 29.71M | 111.71% |
| Dec 31, 2020 | 26.59M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hi-Clearance | 4.19B |
| Wellell | 2.39B |
| InnoCare Optoelectronics | 2.18B |
| Dynamic Medical Technologies | 1.43B |
| WeLeader Biomedical | 1.06B |
| A Plus Biotechnology | 825.52M |
| Delta Asia International | 711.19M |
| Diamond Biotechnology | 698.11M |